PR Newswire October 13, 2021
AION Labs

First-of-its-Kind AI/Pharma and Computational Biology Innovation Lab Appoints Former Senior Pharma Executive as CEO and Senior Computational Scientist as CTO

German BioMed X Institute Introduced as Strategic Partner

REHOVOT, Israel — AION Labs, a first-of-its-kind innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, today announced its official launch and the opening of its international headquarters.

The alliance of four leading pharmaceutical companies – AstraZeneca, Merck, Pfizer and Teva – and two leaders in the hi-tech and biotech investment sphere , respectively – Amazon Web Services Inc. (AWS) and Israel Biotech Fund (IBF) – who have come together with the aim of building groundbreaking AI and computational ventures that will leverage the cloud to...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), Biotechnology, Cloud, Investments, Pharma, Pharma / Biotech, Technology, Trends
Related Articles:
STAT+: After AI protein folding, David Baker’s lab identifies millions of smaller drug candidates
Alphabet shares jump 14% on earnings beat, first-ever dividend
Microsoft: Unlocking AI Benefits Will Require Cultural Changes for Enterprises
Zephyr AI Raises $111 Million in Series A Financing
Chatbot answers are all made up. This new tool helps you figure out which ones to trust.

Share This Article